HONG KONG – Encouraged by new policies to boost drug development, biopharmaceutical companies in China are increasingly investing in innovative drugs overseas that are at late R&D stages and bringing the candidates to the domestic market for further clinical studies.
- Shaky spear? Bard in play for CKD with new wisdom as phase II/III trial begins
- Fusion energized in targeted radiotherapy effort with $25M series A
- Toolgen's AAV delivery could move CRISPR/Cas9 beyond genetic disease
- China's drug reforms will gain traction, but changes are slow
- PMV Pharma raises $74M series B for p53-focused ...
- Beijing's Apollobio to bring Inovio's new HPV drug to China marketplace
- Chi-Med's savolitinib hits phase II endpoints in Met-driven PRCC
- Samsung's biosimilars come to fruition despite scandals, company says
- Germline gene editing should be allowed – in certain situations
- Tivantinib misses OS endpoint in phase III liver...
Although the world-famous groundhog Punxsutawney Phil awoke to see his shadow at the beginning of the month, predicting a further six weeks of winter, thanks to President Donald Trump's vow of a major impending tax announcement, it looks as though biopharmaceutical companies will enjoy an early spring. Their stocks have surged more than 4 percent so far this month in lockstep with the bullish general markets that have hit record highs, with investors believing that the new administration's plans for tax reforms will expand the economy.
LONDON Clinical trials involving genome editing in gametes or early embryos could be permitted in the future, but only for serious conditions and under stringent oversight, said experts after a year-long review of the scientific and ethical issues thrown up by CRISPR/Cas9.READ MORE »
- Potential drug target found for Chikungunya virus arthritis »
- Screening a risky, beneficial business »
- Bacterial immunotherapy shows promise in tumor-targeting »
- 'Bioinspired' culturing process loses serum, gains reproducibility »
- First rotaviruses derived entirely from cloned DNA developed »
- Clotting, hypertension, inflammation linked »
- Plant-derived products may help fight HBV »
- New targets for overcoming melanoma resistance identified »
- Dual-action, dual-indication decoy fights tumors, viruses »
- Is ‘what the patient pays’ the right barometer for pricing drugs?January 26, 2017 | 5:08 PM | Posted by: Mari Serebrov
- Yes, there’s a doctor in the House (and Senate)January 04, 2017 | 12:21 AM | Posted by: Mari Serebrov
- Time for fa-la-la with BioWorld’s 10th annual Holiday Gift GuideDecember 02, 2016 | 8:43 PM | Posted by: Marie Powers
- Biotech’s biggest protesters are turning into its supporters November 30, 2016 | 10:58 PM | Posted by: Amanda Lanier
- Sex and drugs: Something doesn’t ‘Addyi’ upNovember 04, 2016 | 10:35 PM | Posted by: Randy Osborne
Partners in Focus
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST